PT  - JOURNAL ARTICLE
AU  - Rizzo, Toni
ED  - Connolly, Stuart J.
TI  - Long-Term Dabigatran Extension Study for Stroke Prevention in Treatment for Atrial Fibrillation
DP  - 2012  01
TA  - MD Conference Express
PG  - 25--26
VI  - 12
IP  - 18
4099  - http://mdc.sagepub.com/content/12/18/25.short
4100  - http://mdc.sagepub.com/content/12/18/25.full
AB  - Previously, the Randomized Evaluation of Long-Term Anticoagulation Therapy [RE-LY] trial evaluated two doses of dabigatran (110 and 150 mg BID; open dabigatran but blinded dose) versus warfarin (open-label) in patients with nonvalvular atrial fibrillation and at least 1 risk factor for stroke [Flaker et al. J Am Coll Cardiol 2012]. The goal of the RELY-ABLE extension study [NCT00808067] was to describe the long-term efficacy and safety of ongoing dabigatran therapy after the RE-LY trial.